Online inquiry

IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13824MR)

This product GTTS-WQ13824MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ13824MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10752MR IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA M-6495
GTTS-WQ1872MR IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AGEN1884
GTTS-WQ2739MR IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG-139
GTTS-WQ10498MR IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY-2951742
GTTS-WQ8241MR IVTScrip™ mRNA-Anti-KDR, HLX-06(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HLX-06
GTTS-WQ4055MR IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BI 655130
GTTS-WQ13766MR IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-1033
GTTS-WQ11001MR IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MCDS0593A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW